Insulet Corporation's Omnipod® 5 Automated Insulin Delivery System has received FDA clearance for people with type 2 diabetes, making it the first automated insulin delivery system approved for both type 1 and type 2 diabetes. The system continuously adjusts insulin delivery every five minutes based on glucose monitoring, leading to significant improvements in HbA1c levels and overall glycemic control. This approval marks a significant advancement in diabetes management technology, providing a tubeless, wearable option for those requiring insulin therapy.

For more details, visit Drug Delivery Business News, Insulet, or Omnipod.